


## AMENDMENTS TO THE CLAIMS



This listing of claims will replace all prior versions and listings of claims in the application:

### LISTING OF CLAIMS:

1. (original): A uracil derivative represented by the general formula (I):



wherein X represents a group selected from NHCO, NHCH<sub>2</sub>, CO, CONH and CH<sub>2</sub>NH; R<sup>1</sup> represents a hydrogen atom or a substituted or unsubstituted alkyl group of 1 to 6 carbon atoms; R<sup>2</sup> represents the general formula (II) or (III):



wherein m is 0 or 1, n is an integer of 1 to 3, Y is OH or NH<sub>2</sub>, and each dotted line indicates a bonding position, provided that when R<sup>2</sup> represents the general formula (III), X represents NHCO or NHCH<sub>2</sub>; R<sup>3</sup> and R<sup>4</sup> independently represent a hydrogen atom or an alkyl group of 1 to 6 carbon atoms; and Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon

atoms at the o- and m-positions, a substituted or substituted heteroaryl group or a bicyclic aromatic group,  
or a pharmaceutically acceptable salt thereof.

2. (original): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein  $R^2$  represents the general formula (II) in the general formula (I).

3. (original): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein  $R^2$  represents the general formula (III) in the general formula (I).

4. (currently amended): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1-~~or 2~~, wherein Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon atoms at the o- and m-positions in the general formula (I).

5. (currently amended): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1-~~or 2~~, wherein Ar represents a substituted or unsubstituted heteroaryl group in the general formula (I).

6. (currently amended): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1-~~or 2~~, wherein Ar represents a bicyclic aromatic group in the general formula (I).

7. (currently amended): A uracil derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 6~~claim 1, wherein X represents NHCO in the general formula (I).

8. (currently amended): A pharmaceutical composition for the treatment of allergic diseases comprising a uracil derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 7~~claim 1 as an active ingredient.

9. (currently amended): A pharmaceutical composition for the treatment of pruritus comprising a uracil derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claim 1 to 7~~claim 1 as an active ingredient.

10. (new): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 2, wherein Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon atoms at the o- and m-positions in the general formula (I).

11. (new): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 2, wherein Ar represents a substituted or unsubstituted heteroaryl group in the general formula (I).

12. (new): A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 2, wherein Ar represents a bicyclic aromatic group in the general formula (I).